🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr. Yungpeng Yang presents BL-B01D1 (iza-bren) EGFRxHER3 ADC in non-classic EGFR driver+ mNSCLC: ☑️cytopenias most common G3+ AEs ☑️cORR 39.7%, nDOR NR, nOS NR (mFU 8.1mo) ☑️cORR 69.2% in non-classical EGFR, mDOR & mOS NR Very promising drug with early efficacy across drivers

Dr. Yan Huang presents iza-bren (HER3xEGFR ADC) in prev Rxd ES-SCLC: ☑️cORR 48.1%, mDOR 4.6mo, mPFS 4.0mo, mOS 12.0mo ☑️G3+ AEs - hematologic most common Great to see another promising therapeutic in what is becoming a crowded emerging space for ADCs. #ASCO25

Dr. Aaron Lisberg presents DB-1310, novel HER3-ADC, in adv solid tumors. ☑️ well-tolerated with low grade AEs (anemia most common) ☑️ 5% ILD ☑️ 20% cORR, mDOR 6.28mo, mOS 14.4mo ☑️ EGFRm NSCLC: 28.3% cORR, mDOR 5.8mo, mOS 18.89mo Another promising HER3-ADC to watch #ASCO25

🚨 NEW AI tool for oncologists!! ASCO lets you access guideline info fast via chat!! 🔹 Search ASCO’s full guidelines library 🔹 Trusted, cited recommendations 🔹 Supports fast, evidence-based decisions 🔹 Ask follow-up questions 🔗 asco.org/practice-patie… #ASCO25

As presented at #ASCO25: In the phase 2 NeoCOAST-2 platform trial, neoadjuvant durvalumab + chemotherapy + a TROP2-targeting antibody-drug conjugate led to a high pathologic complete response rate in patients with resectable non-small cell #LungCancer nature.com/articles/s4159…

Congratulations to our 🌟 fellow Tina Roy, MD exploring clinical characteristics & treatment outcomes in people living with HIV who develop lung cancer. Georgetown Lombardi. #ASCO25

Great to connect with my amazing friend and former co-med student and co-resident Jacqueline T. Brown, MD of Winship Cancer Institute of Emory University. Pumped for her discussion tmrw "breaking the platinum ceiling in advanced bladder cancer" #ASCO25.

Out now & open access in Nature Medicine concurrent with presentation at #ASCO2025 is NeoCOAST-2! I have been delighted to collaborate on the first platform neoadjuvant trial in lung cancer led by Dr. Tina Cascone nature.com/articles/s4159… ! #LCSM 1/6

🆕 #ASCO25 🆙 ☑️#LCSM Poster 🔥Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in pts with metastatic NSCLC and secondary resistance to immunotherapy 🎙️ Stephen V Liu, MD 📌Poster Bd129a, Abstr TPS8651 OncoAlert ASCO @larvol meetings.asco.org/2025-asco-annu…

#ASCO25 Lung metastatic orals 🔥 Ph II Krystal7 trial: - 149pts (PDL1 >50%: 39pts; 1-49%: 27pts; <1%: 28pts) - ORR 44% - PFS & OS best in PDL1>50% group, as expected - ~50% pts required dose reduction- tox a consideration with this combo ASCO OncoAlert #LCSM

Dr. Tony Mok at #ASCO25 with results from HERTHENA-Lung02 of patritumab deruxtecan (HER3-DXd) vs platinum doublet chemo in #EGFR NSCLC post 3G TKI. PFS 5.7 vs 5.4m, HR 0.77 with numeric improvement in intracranial progression HR 0.75.

🧬 #ASCO25 | OptiTROP-Lung03 Sacituzumab Tirumotecan (sac-TMT) vs docetaxel in EGFRm NSCLC post-TKI 🔹 Primary endpoint (ORR): 45.1% vs 15.6% (p=0.0004) 🔹 PFS: 6.9 vs 2.8 mo (HR 0.30; p<0.0001) 🔹 OS: Not reached, but strong trend (HR 0.49; p=0.007) 🔹 Crossover: 36.4% to

Great to see you, Joshua Reuss ! #ASCO25

Dr. Benjamin Levy presents phase 2 SAVANNAH - randomized subset of savolitinib with osimertinib/placebo in #EGFR NSCLC, MET+ (IHC/FISH) with PD after 1L osimertinib. RR 58% with combo vs 16% with savo alone. In this setting, need to continue EGFR TKI.

Dr. Julia Rotow MD of Dana-Farber's Lowe Center for Thoracic Oncology Plasma-guided intensification from 1L pembro to chemo+pembro in PD-L1+ metastatic NSCLC. mPFS was 11 mo. Further validation needed but opportunities here to spare pts from chemo. ASCO #ASCO25 #lcsm #lcam

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Final OS analysis from CM-816 presented by my incredible mentor Patrick Forde at #ASCO25. ✅️OS HR 0.72 w/ 5yr OS 65% for nivo-chemo vs chemo ✅️strong benefit in PD-L1+ w/ HR 0.51, less robust in PD-L1- w/ HR 0.89 ✅️robust 5yr OS of 95% in patients who achieved pCR!

Dr. Jamie Chaft with NEOADAURA at #ASCO25. Neoadjuvant osimertinib alone or with chemo vs neoadjuvant chemo in NSCLC. MPR only 2% with chemo, vs 25% with osi, 26% with osi/chemo. pCR 9% osi, 4% osi/chemo. EFS better for pts who MPR - curious how adjuvant osi contributed to EFS.

💥 First trial to demonstrate OS benefit in SCLC in the maintenance setting. Lurbinectedin + Atezolizumab hits in ORR, DoR, PFS, and OS. AEs related to lurbi known tox profile. #LCSM #ASCO25 SmallCellSMASHERS

Brigatinib post crizotinib in #ALK NSCLC Clinical Lung Cancer from LudaBazhenovaMD. High response rates seen independent of secondary ALK mutations but if alterations seen in non-ALK secondary drivers (EGFR, KRAS, BRAF, MET0, no responses seen. clinical-lung-cancer.com/article/S1525-…